Galena Biopharma (GALE) Plans Presentation of Interim NeuVax Combo Phase 2b Data at ESMO 2016

September 29, 2016 7:06 AM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Galena Biopharma, Inc. (Nasdaq: GALE) announced that interim safety data from the Company’s NeuVax (nelipepimut-S) Phase 2b combination study will be presented at the upcoming European Society for Medical Oncology (ESMO 2016 Congress in Copenhagen, Denmark. The clinical trial is a randomized, multicenter, investigator-sponsored, 300 patient Phase 2b study. It is currently enrolling HER2 1+ and 2+ node positive, and high-risk node negative patients to study NeuVax in combination with trastuzumab. Details of the poster presentation are as follows:

Poster #: 1069PAbstract #: 3981 – the abstract can be found on the conference website hereTitle: Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expressionDate: Sunday, October 9, 2016Time: 1:00 p.m. to 2:00 p.m. local timeLocation: Hall E

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News

Add Your Comment